modelFerrousSulfate
Extends from Pharmacolibrary.Drugs.ATC.B.B03AA07.
Information
| name: | FerrousSulfate | |
| ATC code: | B03AA07 | route: | oral |
| compartments: | 1 | |
| dosage: | 325 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0.83 | L/h |
| other parameters in model implementation | ||
Ferrous sulfate is an iron supplement used to treat or prevent low blood levels of iron (such as those caused by anemia or during pregnancy). It is commonly prescribed for iron-deficiency anemia and is available in oral formulations. Ferrous sulfate is a well-established and widely used medication approved in many countries.
Pharmacokinetics
Typical pharmacokinetics in healthy adults (non-pregnant, both sexes). PK parameters may vary in special populations (e.g., pregnant women, patients with gastrointestinal disease).
References
Leary, A, et al., & Brunner, V (2016). Pharmacokinetics of Ferrous Sulphate (Tardyferon®) after Single Oral Dose Administration in Women with Iron Deficiency Anaemia. Drug research 66(1) 51–56. DOI:10.1055/s-0035-1549934 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25989284
Leary, A, et al., & Edmond, JM (2017). Iron Pharmacokinetics in Women with Iron Deficiency Anaemia Following A Single Oral Dose of a Novel Formulation of Tardyferon (Prolonged Release Ferrous Sulphate). Drug research 67(11) 647–652. DOI:10.1055/s-0043-113636 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28724166
Troesch, B, et al., & Zimmermann, MB (2011). Fortification iron as ferrous sulfate plus ascorbic acid is more rapidly absorbed than as sodium iron EDTA but neither increases serum nontransferrin-bound iron in women. The Journal of nutrition 141(5) 822–827. DOI:10.3945/jn.110.136127 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21430252
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)